Q3FY18 Results: Eris Lifesciences PAT jumps 10 per cent YoY
Eris Lifesciences reported its results for the quarter ended December 31, 2017 on Monday. The company's consolidated revenue for the quarter came in at Rs. 208.97 crore, registering 13.3 per cent yoy increase.
EBITDA for the quarter rose by 13.1 per cent yoy to Rs. 81.085 crore with a corresponding margin contraction of 5 bps. EBITDA margin for the quarter stood at 38.8 per cent. This margin contraction was led by 36 per cent yoy jump in employee benefit expenses. The PAT for the quarter came in at Rs. 74.92 crore, yoy increase of 10 per cent. This was due to decline in effective tax rate from 5 to 3 per cent in Q3FY18.
Eris Lifesciences is engaged in manufacturing, marketing and selling of generics within the chronic and acute categories of the Indian Pharmaceutical Market.
On Monday, the stock opened at Rs. 765 per share and touched an intra-day high and low of Rs. 782.50 and Rs. 760.35, respectively and finally closed at Rs. 765.05 on the BSE.